BIO-FD&C Co.,Ltd. (KOSDAQ:251120)

Revance Therapeutics Statistics

Total Valuation

BIO-FD&C has a market cap or net worth of KRW 165.91 billion. The enterprise value is 120.02 billion.

Market Cap	165.91B
Enterprise Value	120.02B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

BIO-FD&C has 8.70 million shares outstanding. The number of shares has increased by 0.05% in one year.

Current Share Class	8.70M
Shares Outstanding	8.70M
Shares Change (YoY)	+0.05%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	31.43%
Owned by Institutions (%)	0.22%
Float	5.15M

Valuation Ratios

The trailing PE ratio is 32.24.

PE Ratio	32.24
Forward PE	n/a
PS Ratio	10.00
PB Ratio	2.56
P/TBV Ratio	2.58
P/FCF Ratio	29.73
P/OCF Ratio	27.61
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 18.30, with an EV/FCF ratio of 21.51.

EV / Earnings	23.77
EV / Sales	7.23
EV / EBITDA	18.30
EV / EBIT	22.53
EV / FCF	21.51

Financial Position

The company has a current ratio of 13.18, with a Debt / Equity ratio of 0.02.

Current Ratio	13.18
Quick Ratio	12.44
Debt / Equity	0.02
Debt / EBITDA	0.20
Debt / FCF	0.24
Interest Coverage	81.40

Financial Efficiency

Return on equity (ROE) is 8.11% and return on invested capital (ROIC) is 5.24%.

Return on Equity (ROE)	8.11%
Return on Assets (ROA)	5.01%
Return on Invested Capital (ROIC)	5.24%
Return on Capital Employed (ROCE)	8.20%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.25
Inventory Turnover	2.52

Taxes

In the past 12 months, BIO-FD&C has paid 620.44 million in taxes.

Income Tax	620.44M
Effective Tax Rate	10.94%

Stock Price Statistics

The stock price has increased by +21.25% in the last 52 weeks. The beta is 0.77, so BIO-FD&C's price volatility has been lower than the market average.

Beta (5Y)	0.77
52-Week Price Change	+21.25%
50-Day Moving Average	19,174.60
200-Day Moving Average	15,497.85
Relative Strength Index (RSI)	53.62
Average Volume (20 Days)	37,530

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, BIO-FD&C had revenue of KRW 16.59 billion and earned 5.05 billion in profits. Earnings per share was 591.73.

Revenue	16.59B
Gross Profit	11.66B
Operating Income	5.33B
Pretax Income	5.67B
Net Income	5.05B
EBITDA	6.56B
EBIT	5.33B
Earnings Per Share (EPS)	591.73

Balance Sheet

The company has 47.23 billion in cash and 1.34 billion in debt, giving a net cash position of 45.89 billion or 5,277.48 per share.

Cash & Cash Equivalents	47.23B
Total Debt	1.34B
Net Cash	45.89B
Net Cash Per Share	5,277.48
Equity (Book Value)	64.76B
Book Value Per Share	7,593.08
Working Capital	48.68B

Cash Flow

In the last 12 months, operating cash flow was 6.01 billion and capital expenditures -428.57 million, giving a free cash flow of 5.58 billion.

Operating Cash Flow	6.01B
Capital Expenditures	-428.57M
Free Cash Flow	5.58B
FCF Per Share	641.78

Margins

Gross margin is 70.28%, with operating and profit margins of 32.11% and 30.44%.

Gross Margin	70.28%
Operating Margin	32.11%
Pretax Margin	34.18%
Profit Margin	30.44%
EBITDA Margin	39.53%
EBIT Margin	32.11%
FCF Margin	33.64%

Dividends & Yields

BIO-FD&C does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.05%
Shareholder Yield	n/a
Earnings Yield	3.04%
FCF Yield	3.36%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

BIO-FD&C has an Altman Z-Score of 20.05 and a Piotroski F-Score of 6.

Altman Z-Score	20.05
Piotroski F-Score	6